.
We present hardware verification of continuoustime digital signal processing (CT-DSP) filters using field programmable gate arrays (FPGAs). Our hardware results utilize event-driven data conversion and un-clocked digital logic elements on FPGAs to process pseudo-analog signals in continuoustime (with no discrete-time sampling). Compared to important event-driven CT-DSP topologies previously implemented, the techniques presented here implement broadly applicable filters by trading FPGA resources and ADC resolution for the benefits of low complexity and minimal conversion hardware. We verify several architectures via measurement. These results show realtime filter design primitives that exploit advantages of eventdriven architectures and software re-configurable hardware while suiting applications up to 600 kHz. Altogether, the results demonstrate the validity and effectiveness of CT-DSP implemented using re-configurable and ubiquitous devices.
Background/Objectives: Saponins have recently emerged as promising natural products that enhance toxin-based anticancer therapeutics by improving cytosol uptake. This study aimed to identify structurally defined novel natural saponins and evaluate their ability to enhance anticancer cytotoxicity. Methods: The roots of Saponaria officinalis L. were extracted with aqueous ethanol and purified by silica gel column chromatography and reverse-phase high-performance liquid chromatography (RP HPLC). The structures of new saponins were elucidated by NMR spectroscopy and mass spectrometry. Biological activity was assessed in vitro using multiple cancer cell lines. Results: Two pairs of structurally defined pure saponins were obtained: SO1406 and SO1448, and SO1684 and SO1726. Structural elucidation revealed that SO1684 and SO1726 share the core structure 3-O-β-D-Gal-(1→2)-[β-D-Xyl-(1→3)]-β-D-GlcA-gypsogenin-28-O-β-D-Qui-(1→4)-[β-D-Xyl-(1→3)-β-D-Xyl-(1→4)]-α-L-Rha-(1→2)-β-D-Fuc, with SO1684 acetylated at Qui O-4 and SO1726 bearing additional acetylation at Qui O-3. Deacetylation of either SO1684 or SO1726 afforded a known saponin SA1641 isolated from Saponinum album (Merck). Similarly, SO1406 and SO1448 were identified as 3-O-β-D-Gal-(1→2)-[β-D-Xyl-(1→3)]-β-D-GlcA-gypsogenin-28-O-β-D-Xyl-(1→4)-α-L-Rha-(1→2)-β-D-Fuc derivatives, each acetylated at Fuc O-4, with SO1448 containing an additional acetyl group at Fuc O-3. Among the isolated compounds, SO1684 is a known saponin and SO1406 exhibited the most pronounced biological activity, significantly enhancing the cytotoxicity of the ribosome-inactivating protein saporin (SAP) in the MDA-MB231 (triple-negative breast cancer) cell line. Conclusions: SO1406 demonstrates strong cytotoxicity-enhancing activity, highlighting the significant potential of structurally defined natural saponins to advance intracellular delivery and improve the therapeutic performance of protein-based anticancer agents.
Alzheimer's Disease is a growing health concern, with no available disease-modifying treatments. A previous report suggested that a Delta Opioid Receptor (DOR) antagonist could prevent Alzheimer's-like pathology; however, no DOR antagonists are clinically approved. We thus expanded on our previous structure-activity relationship work on morphinan scaffold DOR antagonists to generate and evaluate new DOR antagonist ligands. We identified a lead compound 12 (SRI-22136) with sub-nM DOR potency, high selectivity, and high inhibition of β-secretase activity. We further evaluated 12 in CD-1 mice, finding full antagonist efficacy at 1 mg/kg by the intraperitoneal route. We then tested the ability of 12 to prevent Alzheimer's-like pathology in a 5XFAD transgenic mouse model, with daily treatment from 2 to 5 months of age. This treatment completely prevented Alzheimer's-like pathology, including memory deficits, β-secretase activity, Aβ1-42 accumulation, and brain inflammatory markers. Together these results suggest 12 as a potential new lead compound to prevent Alzheimer's Disease.
Rationale: Alpha-1 Antitrypsin (A1AT) deficiency is a rare genetic disorder caused by mutations in the SERPINA1 gene, resulting in insufficient levels of functional A1AT protein. This deficiency results in unregulated neutrophil elastase activity in the lung, damaging pulmonary histoarchitecture and causing pathological outcomes, including COPD. Recent developments in respiratory medicine include ReCode's Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform, which currently has two candidates in clinical trials to treat respiratory disease. Moreover, a highly translational ferret model of A1AT deficiency has recently emerged and shown to recapitulate many of the clinical presentations of A1AT deficiency. Thus, the objective of this study was to determine the feasibility of delivering LNP-encapsulated A1AT mRNA to stimulate secretion of functional protein in the local pulmonary microenvironment, utilizing an A1AT KO Ferret model. Methods: We encapsulated a codon-optimized human A1AT mRNA with a LNP previously shown to target the lung (RTX-A1AT) and confirmed bioactivity utilizing A549 cells and an in vitro potency assay. Next, aerosolized RTX-A1AT was delivered intratracheally to A1AT KO ferrets (N=3). Lung tissues and BALF were collected at 24h, and levels of A1AT protein and activity were evaluated with the following methods: A1AT ELISA and LC-MS to confirm the presence of A1AT in the BALF, an elastase inhibition assay to determine the functional activity of translated A1AT, immunohistochemistry to evaluate the localization of A1AT protein expression in the lung. To ensure the translational fidelity of LNP-delivered A1AT, human plasma-derived A1AT protein served as positive control in all assays. Results: In vitro treatment of A549 cells with RTX-A1AT resulted in a dose-dependent increase in secreted, functional, 60-65 kDA glycosylated A1AT into the conditioned media. BALF from an untreated A1AT KO ferret had undetectable levels of A1AT protein. Inhalation delivery of RTX-A1AT resulted in 1949±961ng/ml of protein in the BALF, which is comparable to endogenous levels in healthy human patients. This range was orthogonally confirmed by LC/MS. BALF from treated samples inhibited elastase by 70±7%, whereas untreated BALF exhibited no elastase inhibition activity. Immunohistochemistry indicated that treatment resulted in A1AT expression in the epithelial layer of airways and distinct areas of alveoli. Conclusions: Together, these data provide proof of principle that inhaled, LNP-based mRNA therapy delivers functional, translationally relevant levels of A1AT to the lung. These data represent a unique strategy for A1AT deficiency that differentiates from existing treatment options and has the potential to improve the therapeutic outcomes for the patient population.